Abbott India Limited vs Dr. Lal PathLabs Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Abbott India Limited (Pharmaceuticals) and Dr. Lal PathLabs Limited (Diagnostics and healthcare services) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Abbott India Limited leads on Revenue (approx.) and Net profit (approx.).
Abbott India Limited leads on Revenue (approx.) and Net profit (approx.).
Head-to-head highlights
| Metric | Abbott India Limited | Dr. Lal PathLabs Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | INR 5,800-6,200 crore | Approximately INR 2,200-2,400 crore | AI estimate |
| Net profit (approx.) | INR 1,100-1,300 crore | Approximately INR 350-450 crore | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Abbott India Limited
Pharmaceuticals · India
Abbott India Limited is an Indian pharmaceutical company and a listed subsidiary of Abbott Laboratories. It markets branded prescription and over-the-counter healthcare products across therapeutic areas such as gastroenterology, women's health, metabolic disorders, central nervous system, pain management, and vaccines.
Verified financials
No source-verified financials available.
Strengths
- Strong parentage from Abbott Laboratories
- Recognized brands in chronic and specialty therapeutic areas
- Established doctor and pharmacy distribution network
- Focus on higher-margin branded formulations
Weaknesses
- High dependence on the Indian domestic pharmaceutical market
- Limited scale compared with India's largest pharma companies
- Exposure to price controls on essential medicines
- Relatively concentrated portfolio in select therapies
Opportunities
- Growth in chronic disease treatment demand in India
- Expansion in women's health, gastroenterology, and metabolic care
- Digital engagement with physicians and patients
- Leveraging Abbott's global portfolio for India-specific launches
Threats
- Intense competition from Indian generic and branded-generic companies
- Regulatory pricing pressure from India's drug price control regime
- Changes in physician prescribing behavior
- Supply chain and input cost volatility
Dr. Lal PathLabs Limited
Diagnostics and healthcare services · India
Dr. Lal PathLabs Limited is an Indian diagnostic services company offering pathology, biochemistry, molecular diagnostics, radiology-related services, and preventive health testing. The company operates through a network of laboratories, patient service centers, collection points, and digital/home sample collection channels across India.
Verified financials
No source-verified financials available.
Strengths
- Well-known diagnostics brand in India
- Large hub-and-spoke testing and collection network
- Strong presence in core northern Indian markets
- Broad menu of routine and specialized tests
Weaknesses
- High exposure to competitive pricing in diagnostics
- Geographic concentration relative to some national ambitions
- Dependence on sample volumes and doctor/customer referrals
- Franchise and partner quality control can be operationally complex
Opportunities
- Growth in preventive healthcare and wellness testing
- Expansion in underpenetrated tier-2 and tier-3 cities
- Increased adoption of digital booking and home collection
- Growth in specialized diagnostics and chronic disease monitoring
Threats
- Intense competition from organized chains and local labs
- Regulatory scrutiny over diagnostic pricing and quality standards
- Margin pressure from discounts and aggregator platforms
- Potential disruption from hospital-owned labs and digital health startups
Frequently asked
Answered from source-verified figures on this page.
Abbott India Limited vs Dr. Lal PathLabs Limited: which company leads overall?
Abbott India Limited leads on Revenue (approx.) and Net profit (approx.).
Related market reports
Deep-dive intelligence on the markets these companies compete in.
India Pharmaceutical Sector — Intelligence Report
Global Radiopharmaceuticals and Theranostics Market — Intelligence Report
India Digital Payments Market — Intelligence Report
Global GLP-1 Obesity Drugs, Oral Incretins and Metabolic Health Services Market — Intelligence Report
AI Analyst
Insights and answers generated live from Abbott India Limited vs Dr. Lal PathLabs Limited's verified data. Modeled estimates — not investment advice.
Not enough data yet to generate insights.